for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Cumberland Pharmaceuticals, Inc.

CPIX.OQ

Latest Trade

5.26USD

Change

0.00(0.00%)
0

Today's Range

5.30

 - 

5.30

52 Week Range

4.73

 - 

7.00

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
5.26
Open
5.30
Volume
0
3M AVG Volume
0.71
Today's High
5.30
Today's Low
5.30
52 Week High
7.00
52 Week Low
4.73
Shares Out (MIL)
15.37
Market Cap (MIL)
85.02
Forward P/E
13.83
Dividend (Yield %)
--

Next Event

Q3 2019 Cumberland Pharmaceuticals Inc Earnings Release

Latest Developments

More

Cumberland Pharmaceuticals Announces FDA Orphan Drug Grant Award For New Phase II Clinical Program

Cumberland Says FDA Informed Submission For Update To Caldolor Was Not Accepted For Review

Cumberland Pharmaceuticals Says FDA Sent Co Goal Extension Letter To Allow Additional Time To Review Application For Methotrexate Product Line

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Cumberland Pharmaceuticals, Inc.

Cumberland Pharmaceuticals Inc. (Cumberland) is a specialty pharmaceutical company. The Company is focused on the acquisition, development and commercialization of branded prescription products. The Company operates through specialty pharmaceutical products segment. The Company's product portfolio includes Acetadote (acetylcysteine) Injection for the treatment of acetaminophen poisoning; Caldolor (ibuprofen) Injection for the treatment of pain and fever; Kristalose (lactulose) for Oral Solution for the treatment of chronic and acute constipation; Omeclamox-Pak, (omeprazole, clarithromycin, amoxicillin) for the treatment of Helicobacter pylori (H. pylori) infection and related duodenal ulcer disease; Vaprisol (conivaptan) Injection to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; Hepatoren (ifetroban) Injection, and Boxaban (ifetroban) oral capsules for the treatment of patients with aspirin-exacerbated respiratory disease (AERD).

Industry

Biotechnology & Drugs

Contact Info

2525 W End Ave Ste 950

+1.615.2550068

http://www.cumberlandpharma.com/

Executive Leadership

A. J. Kazimi

Chairman of the Board, Principal Executive Officer

Michael P Bonner

Senior Director Finance and Accounting and Chief Financial Officer

Martin E. Cearnal

Senior Vice President, Chief Commercial Officer, Director

Leo B Pavliv

Senior Vice President - Operations, Chief Development Officer

James L. Herman

Vice President - National Accounts, Chief Compliance Officer

Key Stats

2.50 mean rating - 2 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019(E)

0.0K
EPS (USD)

2018

-0.030

2019(E)

0.400
Price To Earnings (TTM)
--
Price To Sales (TTM)
1.87
Price To Book (MRQ)
1.58
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
37.00
LT Debt To Equity (MRQ)
37.00
Return on Investment (TTM)
-5.65
Return on Equity (TTM)
-4.55

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up